Novo Nordisk Launches Multi-Month Subscriptions for Wegovy Obesity Drugs as It Tries to Catch up with Eli Lilly

Why It Matters

By reducing out‑of‑pocket costs, Novo hopes to retain cash‑pay patients and capture market share from Eli Lilly, whose GLP‑1 products dominate the U.S. obesity market.

Key Takeaways

• Multi‑month subscription reduces Wegovy cost up to $1,200 annually
• Subscriptions available for injection and high‑dose oral pill
• Savings increase with longer commitment: 3‑, 6‑, 12‑month plans
• Program targets cash‑pay patients via telehealth partners
• Aims to retain patients amid 65% dropout rate

Pulse Analysis

The obesity treatment landscape has been reshaped by GLP‑1 drugs, with Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro leading U.S. sales. While Lilly commands roughly 60% of the branded GLP‑1 market, Novo holds about 39% and is racing to expand its footprint. Introducing subscription models mirrors strategies seen in other high‑cost therapeutics, where predictable pricing can lower barriers for patients who otherwise face steep monthly bills. This approach also aligns with broader industry trends toward value‑based pricing and patient‑centric care.

Novo’s subscription tiers—three, six and twelve months—offer flat monthly rates that decrease as commitment lengthens. For the injection, patients can pay $329, $299 or $249 per month, translating to $240, $600 or $1,200 in yearly savings respectively. The oral pill sees similar discounts, with the 12‑month plan costing $249 monthly and saving $600 annually. By partnering with telehealth platforms like Ro and Hims & Hers, Novo reaches cash‑pay consumers directly, simplifying enrollment and fostering continuity of care. The structure also cushions patients against dose changes, ensuring price stability even if they switch formulations.

The subscription launch arrives as Eli Lilly prepares to roll out its own oral GLP‑1 later this year, intensifying competition for new patients transitioning from injections. Novo’s pricing incentive aims to lock in users before the rival product gains traction, potentially curbing the high 65% attrition rate observed in obesity therapy. If successful, the model could boost Novo’s market share, set a precedent for other biotech firms, and influence payer negotiations by demonstrating a viable pathway to sustained, affordable access for high‑cost specialty drugs.